{"count": 20, "results": [{"_id": "34048395", "pmid": 34048395, "title": "Preventive Migraine Treatment.", "journal": "Continuum (Minneap Minn)", "authors": ["Burch R"], "date": "2021-06-01T00:00:00Z", "doi": "10.1212/CON.0000000000000957", "meta_date_publication": "2021 Jun 1", "meta_volume": "27", "meta_issue": "3", "meta_pages": "613-632", "score": 50264.6, "text_hl": "Since the commonly cited 2012 American @DISEASE_Headache @DISEASE_MESH:D006261 @@@Headache@@@ Society/American Academy of Neurology @<m>DISEASE_Migraine_Disorders</m> @DISEASE_MESH:D008881 @@@migraine@@@ prevention guidelines were released, clinical trials supporting the preventive use of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@, @CHEMICAL_candesartan @CHEMICAL_MESH:C081643 @@@candesartan@@@, and @CHEMICAL_Memantine @CHEMICAL_MESH:D008559 @@@memantine@@@ have been published. ", "citations": {"NLM": "Burch R. Preventive Migraine Treatment. Continuum (Minneap Minn). 2021 Jun 1;27(3):613-632. PMID: 34048395", "BibTeX": "@article{34048395, title={Preventive Migraine Treatment.}, author={Burch R}, journal={Continuum (Minneap Minn)}, volume={27}, number={3}, pages={613-632}}"}}, {"_id": "38307673", "pmid": 38307673, "title": "Preventive treatment of migraine: Non-specific oral agents.", "journal": "Handb Clin Neurol", "authors": ["Tronvik E", "Giri S", "Young W"], "date": "2024-01-01T00:00:00Z", "doi": "10.1016/B978-0-12-823357-3.00009-4", "meta_date_publication": "2024", "meta_volume": "199", "meta_issue": "", "meta_pages": "67-86", "score": 50263.06, "text_hl": "Preventive treatment of @<m>DISEASE_Migraine_Disorders</m> @DISEASE_MESH:D008881 @@@migraine@@@: Non-specific oral agents.", "citations": {"NLM": "Tronvik E, Giri S, Young W. Preventive treatment of migraine: Non-specific oral agents. Handb Clin Neurol. 2024;199():67-86. PMID: 38307673", "BibTeX": "@article{38307673, title={Preventive treatment of migraine: Non-specific oral agents.}, author={Tronvik E and Giri S and Young W}, journal={Handb Clin Neurol}, volume={199}, pages={67-86}}"}}, {"_id": "39899861", "pmid": 39899861, "title": "Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians.", "journal": "Ann Intern Med", "authors": ["Qaseem A", "Cooney TG", "Etxeandia-Ikobaltzeta I", "Wilt TJ", "Harrod CS", "Tice JA", "Crandall CJ", "Clinical Guidelines Committee of the American College of Physicians", "Hicks LA", "Cross JT Jr", "Fitterman N", "Lewis J", "Linsky AM", "Maroto M", "Miller MC", "Obley AJ", "Owens DK", "Shekelle PG", "Shamliyan T", "Yost J"], "date": "2025-02-04T00:00:00Z", "doi": "10.7326/ANNALS-24-01052", "meta_date_publication": "2025 Feb 4", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50249.145, "text_hl": "ACP used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to analyze the effects of pharmacologic treatment on the following outcomes: @<m>DISEASE_Migraine_Disorders</m> @DISEASE_MESH:D008881 @@@migraine@@@ frequency and duration, number of days medication was taken for acute treatment of @<m>DISEASE_Migraine_Disorders</m> @DISEASE_MESH:D008881 @@@migraine@@@, frequency of @<m>DISEASE_Migraine_Disorders</m> @DISEASE_MESH:D008881 @@@migraine@@@-related emergency department visits, @<m>DISEASE_Migraine_Disorders</m> @DISEASE_MESH:D008881 @@@migraine@@@-related disability, quality of life and physical functioning, and discontinuations due to adverse events. ", "citations": {"NLM": "Qaseem A, Cooney TG, Etxeandia-Ikobaltzeta I, Wilt TJ, Harrod CS, Tice JA, Crandall CJ, Clinical Guidelines Committee of the American College of Physicians, Hicks LA, Cross JT Jr, Fitterman N, Lewis J, Linsky AM, Maroto M, Miller MC, Obley AJ, Owens DK, Shekelle PG, Shamliyan T, Yost J. Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians. Ann Intern Med. 2025 Feb 4;():. PMID: 39899861", "BibTeX": "@article{39899861, title={Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians.}, author={Qaseem A and Cooney TG and Etxeandia-Ikobaltzeta I and Wilt TJ and Harrod CS and Tice JA and Crandall CJ and Clinical Guidelines Committee of the American College of Physicians and Hicks LA and Cross JT Jr and Fitterman N and Lewis J and Linsky AM and Maroto M and Miller MC and Obley AJ and Owens DK and Shekelle PG and Shamliyan T and Yost J}, journal={Ann Intern Med}}"}}, {"_id": "39467289", "pmid": 39467289, "title": "2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for the Management of Headache.", "journal": "Ann Intern Med", "authors": ["Sico JJ", "Antonovich NM", "Ballard-Hernandez J", "Buelt AC", "Grinberg AS", "Macedo FJ", "Pace IW", "Reston J", "Sall J", "Sandbrink F", "Skop KM", "Stark TR", "Vogsland R", "Wayman L", "Ford AW"], "date": "2024-10-29T00:00:00Z", "doi": "10.7326/ANNALS-24-00551", "meta_date_publication": "2024 Oct 29", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50247.402, "text_hl": "In addition to @CHEMICAL_Tryptamines @CHEMICAL_MESH:D014363 @@@triptans@@@ and @CHEMICAL_Aspirin @CHEMICAL_MESH:D001241 @@@aspirin@@@-@CHEMICAL_Acetaminophen @CHEMICAL_MESH:D000082 @@@acetaminophen@@@-@CHEMICAL_Caffeine @CHEMICAL_MESH:D002110 @@@caffeine@@@, newer calcitonin gene-related peptide (CGRP) inhibitors (gepants) are options for treatment of @<m>DISEASE_Migraine_Disorders</m> @DISEASE_MESH:D008881 @@@acute migraine@@@. Medications to prevent @<m>DISEASE_Migraine_Disorders</m> @DISEASE_MESH:D008881 @@@episodic migraine@@@ (@<m>DISEASE_Migraine_Disorders</m> @DISEASE_MESH:D008881 @@@EM@@@) include angiotensin-receptor blockers, @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@, @CHEMICAL_Magnesium @CHEMICAL_MESH:D008274 @@@magnesium@@@, @CHEMICAL_Topiramate @CHEMICAL_MESH:D000077236 @@@topiramate@@@, @CHEMICAL_Valproic_Acid @CHEMICAL_MESH:D014635 @@@valproate@@@, @CHEMICAL_Memantine @CHEMICAL_MESH:D008559 @@@memantine@@@, the newer CGRP monoclonal antibodies, and @CHEMICAL_atogepant @CHEMICAL_MESH:C000718987 @@@atogepant@@@. ", "citations": {"NLM": "Sico JJ, Antonovich NM, Ballard-Hernandez J, Buelt AC, Grinberg AS, Macedo FJ, Pace IW, Reston J, Sall J, Sandbrink F, Skop KM, Stark TR, Vogsland R, Wayman L, Ford AW. 2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for the Management of Headache. Ann Intern Med. 2024 Oct 29;():. PMID: 39467289", "BibTeX": "@article{39467289, title={2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for the Management of Headache.}, author={Sico JJ and Antonovich NM and Ballard-Hernandez J and Buelt AC and Grinberg AS and Macedo FJ and Pace IW and Reston J and Sall J and Sandbrink F and Skop KM and Stark TR and Vogsland R and Wayman L and Ford AW}, journal={Ann Intern Med}}"}}, {"_id": "17539955", "pmid": 17539955, "title": "Efficacy of lisinopril in migraine prophylaxis--an open label study.", "journal": "Eur J Neurol", "authors": ["Schuh-Hofer S", "Flach U", "Meisel A", "Israel H", "Reuter U", "Arnold G"], "date": "2007-06-01T00:00:00Z", "doi": "10.1111/j.1468-1331.2007.01764.x", "meta_date_publication": "2007 Jun", "meta_volume": "14", "meta_issue": "6", "meta_pages": "701-3", "score": 50085.848, "text_hl": "Efficacy of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ in @<m>DISEASE_Migraine_Disorders</m> @DISEASE_MESH:D008881 @@@migraine@@@ prophylaxis--an open label study.", "citations": {"NLM": "Schuh-Hofer S, Flach U, Meisel A, Israel H, Reuter U, Arnold G. Efficacy of lisinopril in migraine prophylaxis--an open label study. Eur J Neurol. 2007 Jun;14(6):701-3. PMID: 17539955", "BibTeX": "@article{17539955, title={Efficacy of lisinopril in migraine prophylaxis--an open label study.}, author={Schuh-Hofer S and Flach U and Meisel A and Israel H and Reuter U and Arnold G}, journal={Eur J Neurol}, volume={14}, number={6}, pages={701-3}}"}}, {"_id": "11141144", "pmid": 11141144, "title": "Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study.", "journal": "BMJ", "authors": ["Schrader H", "Stovner LJ", "Helde G", "Sand T", "Bovim G"], "date": "2001-01-06T00:00:00Z", "doi": "10.1136/bmj.322.7277.19", "meta_date_publication": "2001 Jan 6", "meta_volume": "322", "meta_issue": "7277", "meta_pages": "19-22", "score": 50071.223, "text_hl": "Prophylactic treatment of @<m>DISEASE_Migraine_Disorders</m> @DISEASE_MESH:D008881 @@@migraine@@@ with angiotensin converting enzyme inhibitor (@<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@): randomised, placebo controlled, crossover study.", "citations": {"NLM": "Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ. 2001 Jan 6;322(7277):19-22. PMID: 11141144", "BibTeX": "@article{11141144, title={Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study.}, author={Schrader H and Stovner LJ and Helde G and Sand T and Bovim G}, journal={BMJ}, volume={322}, number={7277}, pages={19-22}}"}}, {"_id": "7591740", "pmid": 7591740, "title": "ACE inhibitors for prophylaxis of migraine headaches.", "journal": "Headache", "authors": ["Bender WI"], "date": "1995-09-01T00:00:00Z", "doi": "10.1111/j.1526-4610.1995.hed3508470.x", "meta_date_publication": "1995 Sep", "meta_volume": "35", "meta_issue": "8", "meta_pages": "470-1", "score": 50070.008, "text_hl": "ACE inhibitors for prophylaxis of @<m>DISEASE_Migraine_Disorders</m> @DISEASE_MESH:D008881 @@@migraine headaches@@@.", "citations": {"NLM": "Bender WI. ACE inhibitors for prophylaxis of migraine headaches. Headache. 1995 Sep;35(8):470-1. PMID: 7591740", "BibTeX": "@article{7591740, title={ACE inhibitors for prophylaxis of migraine headaches.}, author={Bender WI}, journal={Headache}, volume={35}, number={8}, pages={470-1}}"}}, {"_id": "29971804", "pmid": 29971804, "title": "An evidence-based systematic review of the off-label uses of lisinopril.", "journal": "Br J Clin Pharmacol", "authors": ["Sadat-Ebrahimi SR", "Parnianfard N", "Vahed N", "Babaei H", "Ghojazadeh M", "Tang S", "Azarpazhooh A"], "date": "2018-11-01T00:00:00Z", "doi": "10.1111/bcp.13705", "meta_date_publication": "2018 Nov", "meta_volume": "84", "meta_issue": "11", "meta_pages": "2502-2521", "score": 50069.785, "text_hl": "An evidence-based systematic review of the off-label uses of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@.", "citations": {"NLM": "Sadat-Ebrahimi SR, Parnianfard N, Vahed N, Babaei H, Ghojazadeh M, Tang S, Azarpazhooh A. An evidence-based systematic review of the off-label uses of lisinopril. Br J Clin Pharmacol. 2018 Nov;84(11):2502-2521. PMID: 29971804", "BibTeX": "@article{29971804, title={An evidence-based systematic review of the off-label uses of lisinopril.}, author={Sadat-Ebrahimi SR and Parnianfard N and Vahed N and Babaei H and Ghojazadeh M and Tang S and Azarpazhooh A}, journal={Br J Clin Pharmacol}, volume={84}, number={11}, pages={2502-2521}}"}}, {"_id": "22614308", "pmid": 22614308, "title": "[Prophylactic medicines for migraine].", "journal": "Tidsskr Nor Laegeforen", "authors": ["Stovner LJ", "Tronvik E", "Hagen K"], "date": "2012-05-15T00:00:00Z", "doi": "10.4045/tidsskr.11.1515", "meta_date_publication": "2012 May 15", "meta_volume": "132", "meta_issue": "9", "meta_pages": "1094-6", "score": 50069.69, "text_hl": "Drugs licensed in Norway with adequate  scientific documentation for use as @<m>DISEASE_Migraine_Disorders</m> @DISEASE_MESH:D008881 @@@migraine@@@ prophylactics include  some antihypertensives (beta-blockers, @CHEMICAL_candesartan @CHEMICAL_MESH:C081643 @@@candesartan@@@ and @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@),  antiepileptics (@CHEMICAL_Topiramate @CHEMICAL_MESH:D000077236 @@@topiramate@@@, @CHEMICAL_Valproic_Acid @CHEMICAL_MESH:D014635 @@@valproate@@@ and @CHEMICAL_Gabapentin @CHEMICAL_MESH:D000077206 @@@gabapentin@@@), an antidepressant (@CHEMICAL_Amitriptyline @CHEMICAL_MESH:D000639 @@@amitriptyline@@@),  and botulinum toxin for chronic @<m>DISEASE_Migraine_Disorders</m> @DISEASE_MESH:D008881 @@@migraine@@@. ", "citations": {"NLM": "Stovner LJ, Tronvik E, Hagen K. [Prophylactic medicines for migraine]. Tidsskr Nor Laegeforen. 2012 May 15;132(9):1094-6. PMID: 22614308", "BibTeX": "@article{22614308, title={[Prophylactic medicines for migraine].}, author={Stovner LJ and Tronvik E and Hagen K}, journal={Tidsskr Nor Laegeforen}, volume={132}, number={9}, pages={1094-6}}"}}, {"_id": "25618859", "pmid": 25618859, "title": "[Role of antihypertensive drugs in the treatment of migraine].", "journal": "Orv Hetil", "authors": ["Fehér G", "Pusch G"], "date": "2015-02-01T00:00:00Z", "doi": "10.1556/OH.2015.30056", "meta_date_publication": "2015 Feb 1", "meta_volume": "156", "meta_issue": "5", "meta_pages": "179-85", "score": 50065.984, "text_hl": "Current evidence supports the use of angiotensin converting enzyme inhibitors (mainly @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@) and angiotensin receptor blockers (mainly @CHEMICAL_candesartan @CHEMICAL_MESH:C081643 @@@candesartan@@@) for long-term @<m>DISEASE_Migraine_Disorders</m> @DISEASE_MESH:D008881 @@@migraine@@@ prevention and blood pressure control. ", "citations": {"NLM": "Fehér G, Pusch G. [Role of antihypertensive drugs in the treatment of migraine]. Orv Hetil. 2015 Feb 1;156(5):179-85. PMID: 25618859", "BibTeX": "@article{25618859, title={[Role of antihypertensive drugs in the treatment of migraine].}, author={Fehér G and Pusch G}, journal={Orv Hetil}, volume={156}, number={5}, pages={179-85}}"}}]}